We reported before that rivastigmine, a United States Food and Drug Administration (FDA)-approved anti-amnestic drug currently under preclinical studies for mild or moderate AD (Alhazmi and Albratty, 2022; Rountree et al., 2013), lowered the frequency of tight MAMs and reduced Aβ generation in vitro cellular model of AD (neuro-2A cells constitutively expressing human APP; N2AAPP) in a dose-dependent manner (Zellmer et al., 2024; Zellmer et al., 2025). The gene discussed is APP; the disease is Alzheimer disease.